Medtronic announces results showing meaningful pain relief using DTM Spinal Cord Stimulation endurance therapy.
At 3 months, patients treated with DTM SCS endurance therapy reported meaningful pain relief as measured by a 3.9 cm reduction in overall pain on the 10 cm Visual Analog Scale (VAS). Patients also reported an average 4.3 cm decrease in back pain, and an average 5.0 cm decrease in leg pain. The Visual Analog Scale (VAS) is a widely used and accepted measure for pain intensity that captures patient-reported pain levels on a scale of 0-10. These 3-month results are consistent with those of a prior feasibility study and add to the body of DTM SCS evidence demonstrating that DTM SCS endurance therapy can provide effective pain relief along with additional quality of life and functional benefits for patients.
Additional 3-month data include : i. 69% of patients improved to a less disabled category as measured by the Oswestry Disability Index, with 63% having minimal or moderate disability at 3-months compared to just 16% at baseline ii. 75% of patients were very satisfied or somewhat satisfied with their therapy at 3-months. Modeling based on actual three-month data also shows that DTM SCS endurance therapy enables between 5.5-7.5 years device longevity when programmed on the Vanta recharge-free neurostimulator. For those in need of a rechargeable device, DTM SCS endurance therapy programmed on the Intellis rechargeable neurostimulator allows either rapid recharge (5 minutes per day) or recharges of approximately one hour every 12 days.
"These 3-month results are highly encouraging, as they demonstrate that the DTM SCS endurance therapy may be able to provide effective pain relief while dosing at lower energy than other SCS waveforms. This may improve device longevity and offers validation of therapy for the patients who would need it," said Dr. Kasra Amirdelfan, director of Clinical Research at IPM Medical Group, Inc. and principal investigator on the DTM-LE Trial.
Enrolled patients will have additional follow-up assessments at 6 and 12 months. These data were first shared at the 25th Annual North American Neuromodulation Society (NANS) Annual Meeting, January 13-15 2022.
Related news and insights
Gilead Sciences, Inc. announced the FDA has lifted the clinical hold placed on the company’s Investigational New Drug Application (IND) to evaluate injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP).
Bristol Myers Squibb announced the Phase III CheckMate -901 trial, comparing Opdivo (nivolumab) plus Yervoy (ipilimumab) to standard-of-care chemotherapy as a first-line treatment for patients with untreated unresectable or metastatic urothelial carcinoma, did not meet the primary endpoint of overall survival (OS) in patients whose tumor cells express PD-L1 greater than 1% at final analysis.
Santen Pharmaceutical has obtained Chinese regulatory approval for Verkazia (ciclosporin) eye drops for the treatment of severe vernal keratoconjunctivitis (VKC) in children and adolescents aged four years and older.